Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 571 (LINC00571)
- Target
- LINC00571
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA)
01
Overview
Long intergenic non-protein coding RNA 571 (LINC00571) is a long intergenic non-coding RNA, primarily localized in the nucleus, and composed of 6 exons[2]. It is upregulated in triple-negative breast cancer (TNBC), where it acts as a scaffold to facilitate protein–protein interactions between HNRNPK and ILF2, leading to enhanced ILF2 stability and subsequent activation of downstream genes such as IDH2, a regulator of the TCA cycle[2]. LINC00571 promotes cancer cell proliferation, modulates the cell cycle, inhibits apoptosis, and drives metabolic reprogramming of tumor cells[2][4]. Its aberrant expression is associated with poor prognosis in TNBC, lymphatic and distant metastasis, high Ki-67, and tumor differentiation, highlighting its value as a biomarker and potential indirect therapeutic target[2]. Direct targeting approaches, however, are not in clinical use.
- Other names
- LINC00571Long intergenic non-protein coding RNA 571
02
Mechanism of action
Not applicable. There are no drugs with a direct mechanism of action targeting LINC00571
03
Biological functions
Regulation of cell proliferationRegulation of cell cycle progressionRegulation of apoptosisRegulation of tricarboxylic acid (TCA) cycle metabolismScaffold for protein interactions, modulating protein stability and functionGene expression regulation (via interactions with RNA-binding proteins)
04
Disease associations
Cancer (specifically, triple-negative breast cancer)Other (potentially other cancers given the general role of lncRNAs, but specific evidence here is for breast cancer)
05
Safety considerations
No direct safety concerns reported, as there are no therapeutics targeting LINC00571 in clinical use or evaluation. However, as a potential biomarker or gene therapy target, the general risks of oligonucleotide/gene-targeting strategies could be considered but are not specifically described here
06
Biomarkers
High expression of LINC00571 (for triple-negative breast cancer prognosis and potentially as a diagnostic/prognostic biomarker)
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 571 (LINC00571).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 571 (LINC00571).